262 related articles for article (PubMed ID: 28345026)
1. Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.
Havunen R; Siurala M; Sorsa S; Grönberg-Vähä-Koskela S; Behr M; Tähtinen S; Santos JM; Karell P; Rusanen J; Nettelbeck DM; Ehrhardt A; Kanerva A; Hemminki A
Mol Ther Oncolytics; 2017 Mar; 4():77-86. PubMed ID: 28345026
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.
Santos JM; Cervera-Carrascon V; Havunen R; Zafar S; Siurala M; Sorsa S; Anttila M; Kanerva A; Hemminki A
Mol Ther; 2018 Sep; 26(9):2243-2254. PubMed ID: 30017877
[TBL] [Abstract][Full Text] [Related]
4. Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting.
Siurala M; Vähä-Koskela M; Havunen R; Tähtinen S; Bramante S; Parviainen S; Mathis JM; Kanerva A; Hemminki A
Oncoimmunology; 2016 May; 5(5):e1136046. PubMed ID: 27467954
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors.
Cervera-Carrascon V; Quixabeira DCA; Havunen R; Santos JM; Kutvonen E; Clubb JHA; Siurala M; Heiniö C; Zafar S; Koivula T; Lumen D; Vaha M; Garcia-Horsman A; Airaksinen AJ; Sorsa S; Anttila M; Hukkanen V; Kanerva A; Hemminki A
Mol Ther Oncolytics; 2020 Jun; 17():47-60. PubMed ID: 32322662
[TBL] [Abstract][Full Text] [Related]
6. Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.
Santos J; Heiniö C; Quixabeira D; Zafar S; Clubb J; Pakola S; Cervera-Carrascon V; Havunen R; Kanerva A; Hemminki A
Cells; 2021 Apr; 10(5):. PubMed ID: 33922052
[TBL] [Abstract][Full Text] [Related]
7. Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.
Havunen R; Santos JM; Sorsa S; Rantapero T; Lumen D; Siurala M; Airaksinen AJ; Cervera-Carrascon V; Tähtinen S; Kanerva A; Hemminki A
Mol Ther Oncolytics; 2018 Dec; 11():109-121. PubMed ID: 30569015
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.
Siurala M; Havunen R; Saha D; Lumen D; Airaksinen AJ; Tähtinen S; Cervera-Carrascon V; Bramante S; Parviainen S; Vähä-Koskela M; Kanerva A; Hemminki A
Mol Ther; 2016 Aug; 24(8):1435-43. PubMed ID: 27357626
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control.
Quixabeira DCA; Zafar S; Santos JM; Cervera-Carrascon V; Havunen R; Kudling TV; Basnet S; Anttila M; Kanerva A; Hemminki A
Front Immunol; 2021; 12():674400. PubMed ID: 34084172
[TBL] [Abstract][Full Text] [Related]
10. Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.
Santos JM; Havunen R; Siurala M; Cervera-Carrascon V; Tähtinen S; Sorsa S; Anttila M; Karell P; Kanerva A; Hemminki A
Int J Cancer; 2017 Oct; 141(7):1458-1468. PubMed ID: 28614908
[TBL] [Abstract][Full Text] [Related]
11. Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression.
Kudling TV; Clubb JHA; Quixabeira DCA; Santos JM; Havunen R; Kononov A; Heiniö C; Cervera-Carrascon V; Pakola S; Basnet S; Grönberg-Vähä-Koskela S; Arias V; Gladwyn-Ng I; Aro K; Bäck L; Räsänen J; Ilonen I; Borenius K; Räsänen M; Hemminki O; Rannikko A; Kanerva A; Tapper J; Hemminki A
Oncoimmunology; 2022; 11(1):2096572. PubMed ID: 35845722
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.
Cervera-Carrascon V; Quixabeira DCA; Santos JM; Havunen R; Zafar S; Hemminki O; Heiniö C; Munaro E; Siurala M; Sorsa S; Mirtti T; Järvinen P; Mildh M; Nisen H; Rannikko A; Anttila M; Kanerva A; Hemminki A
Oncoimmunology; 2020 May; 9(1):1761229. PubMed ID: 32923123
[TBL] [Abstract][Full Text] [Related]
13. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
Tähtinen S; Blattner C; Vähä-Koskela M; Saha D; Siurala M; Parviainen S; Utikal J; Kanerva A; Umansky V; Hemminki A
J Immunother; 2016; 39(9):343-354. PubMed ID: 27741089
[TBL] [Abstract][Full Text] [Related]
14. Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus.
Hirvinen M; Rajecki M; Kapanen M; Parviainen S; Rouvinen-Lagerström N; Diaconu I; Nokisalmi P; Tenhunen M; Hemminki A; Cerullo V
Hum Gene Ther; 2015 Mar; 26(3):134-44. PubMed ID: 25557131
[TBL] [Abstract][Full Text] [Related]
15. Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine.
Quixabeira DCA; Jirovec E; Pakola S; Havunen R; Basnet S; Santos JM; Kudling TV; Clubb JHA; Haybout L; Arias V; Grönberg-Vähä-Koskela S; Cervera-Carrascon V; Pasanen A; Anttila M; Tapper J; Kanerva A; Hemminki A
Cancer Gene Ther; 2023 Nov; 30(11):1543-1553. PubMed ID: 37666898
[TBL] [Abstract][Full Text] [Related]
16. TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.
Cervera-Carrascon V; Siurala M; Santos JM; Havunen R; Tähtinen S; Karell P; Sorsa S; Kanerva A; Hemminki A
Oncoimmunology; 2018; 7(5):e1412902. PubMed ID: 29721366
[TBL] [Abstract][Full Text] [Related]
17. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
Steger GG; Pierce WC; Figlin R; Czernin J; Kaboo R; DeKernion JB; Okarma T; Belldegrun A
Clin Immunol Immunopathol; 1994 Aug; 72(2):237-47. PubMed ID: 8050198
[TBL] [Abstract][Full Text] [Related]
18. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.
Tähtinen S; Grönberg-Vähä-Koskela S; Lumen D; Merisalo-Soikkeli M; Siurala M; Airaksinen AJ; Vähä-Koskela M; Hemminki A
Cancer Immunol Res; 2015 Aug; 3(8):915-25. PubMed ID: 25977260
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of high doses versus low doses of interleukin-12 on the adoptive transfer of human specific cytotoxic T lymphocyte in autologous lung tumors engrafted into severe combined immunodeficiency disease-nonobese diabetic mice: relation with interleukin-10 induction.
Asselin-Paturel C; Megherat S; Vergnon I; Echchakir H; Dorothée G; Blesson S; Gay F; Mami-Chouaib F; Chouaib S
Cancer; 2001 Jan; 91(1):113-22. PubMed ID: 11148567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
